NP 61Alternative Names: NP 0361; NP-61
Latest Information Update: 07 Mar 2013
At a glance
- Originator Neuropharma
- Class Antidementias; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Alzheimer's disease